PEARSON, Andrew D J, Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA, Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA and Gilles VASSAL. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer. Oxford: Elsevier Science Inc., 2022, vol. 160, January 2022, p. 112-133. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2021.10.016.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Authors PEARSON, Andrew D J (guarantor), Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA and Gilles VASSAL.
Edition European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.400
RIV identification code RIV/00216224:14110/22:00128488
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ejca.2021.10.016
UT WoS 000792599600009
Keywords in English Paediatric oncology; CAR T-cell; Adoptive cellular immunotherapy; Paediatric Strategy Forum; Drug development; Cancer therapeutics
Tags 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 1/2/2023 14:29.
Abstract
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children.
PrintDisplayed: 22/7/2024 20:23